The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?
Since the March bottom, small caps have outperformed large caps, but in the last month, larger firms have come on stronger. So where should you put your money? Portfolio managers Mary Jane Matts of Fifth Third Large Cap Value Fund and Bob Sullivan of Satuit Capital Microcap Fund shared their insights.
Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.
New York Attorney General Andrew Cuomo filed some salacious charges this morning, accusing Intel of using "illegal threats and collusion" to control the microprocessor market.
Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.
Where should investors be putting their money—and what should they avoid? Doug Kreps, principal and managing director at Fort Pitt Capital Group, and Brett D’arcy, CIO of CBIZ Wealth Management, shared their investing “tricks and treats” in honor of Halloween.
New York Attorney General Andrew Cuomo and 14 other states are filing a lawsuit against Amgen, alleging that the biotech company was offering kickbacks to medical providers to increase the sale of its anemia drug Aranesp.
Cramer makes the call on viewers' favorite stocks.
At the end of September, we looked at analysts' price targets for the S&P 500 to see which stocks had the greatest expected gains in the months ahead. So far, 3 out of the October 1 top 5 and 6 out of the top 10 are trading to the upside. Here is the current list of 15 stocks expected to pop (and another 15 expected to drop).
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.
Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.
Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices.
With Amgen dropping after hours and Merck, Celgene and others reporting earnings on Thursday, how should you game health care?
Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.
Stocks finished lower after well-known banking analyst Dick Bove downgraded his rating on Wells Fargo.
Stocks advanced Wednesday as investors were encouraged by a few earnings reports, including Morgan Stanley, Yahoo and SanDisk. The VIX, widely considered the best gauge of fear in the market, dropped to just above 20.
Stocks opened lower Wednesday as a raft of companies beating earning estimates but failed to impress investors.
Earnings season continues in earnest Wednesday, as we roll on with a week that will ultimately see 25 percent of the S&P 500 report their quarterly numbers.
Biotech investors will be closely watching results from Amgen on Wednesday. How should you game this stock into earnings?